As shown in Fig. 4d, while DOX + Ara-C treatment alone only moderately (though statistically significantly) improved survival in mice carrying MLL-AF9 AML, forced expression of Alox5 dramatically improved the response of MLL-AF9 AML to the DOX + Ara-C treatment (Fig. 4d). Here, ALOX5 is linked to acute myeloid leukemia.